Claims for Patent: 6,028,164

Summary for Patent: 6,028,164

Title:	Bioresorbable compositions for implantable prostheses
Abstract:	Crosslinked compositions formed from a water-insoluble copolymer are disclosed. These compositions are copolymers having a bioresorbable region, a hydrophilic region and at least two crosslinkable functional groups per polymer chain. These compositions are able to form hydrogels in aqueous environments when crosslinked. These hydrogels are good sealants for implantable prostheses when in contact with an aqueous environment. In addition, such hydrogels can be used as delivery vehicles for therapeutic agents.
Inventor(s):	Loomis; Gary L. (Morristown, NJ)
Assignee:	Meadox Medicals, Inc. (Oakland, NJ)
Application Number:	09/243,379
Patent Claims:	1. A covalently crosslinkable composition comprising a polymerizable compound corresponding to the following general formula: ##STR2## wherein x is from about 10 to about 50 and y is from about 50 to about 300. 2. The composition of claim 1, wherein said polymerizable compound has (1) a bioresorbable region; (2) a hydrophilic region; and (3) a plurality of crosslinkable functional groups per polymer chain. 3. The composition of claim 2, wherein said bioresorbable region is hydrophobic. 4. The composition of claim 2, wherein said bioresorbable region has hydrophilic character without rendering the polymerizable compound water-soluble. 5. The composition of claim 2, wherein said bioresorbable region is hydrolytically and/or enzymatically cleavable. 6. The composition of claim 2, wherein said hydrophilic region forms an excretable and/or metabolizable fragment. 7. The composition of claim 2, wherein the relative properties and proportions of said bioresorbable region and said hydrophilic region are selected to render said composition insoluble in water. 8. The composition of claim 1, wherein said composition is crosslinkable by high energy, thermal radiation, or visible light. 9. The composition of claim 1 further comprising a free radical initiator. 10. The composition of claim 9, wherein said free radical initiator is a peroxide or an azo compound. 11. The composition of claim 10, wherein said azo compound is 2,2'-Azobis (N,N'dimethyleneisobutyramidine) dihydrochloride. 12. The composition of claim 1, wherein said polymerizable compound is crosslinkable in a non-humid environment. 13. The composition of claim 1, wherein said polymerizable compound is crosslinkable in a humid environment. 14. The composition of claim 13, wherein said humid environment contains from about 20% to about 100% water, preferably from about 60% to about 100% water. 15. The composition of claim 1, wherein said polymerizable compound forms a hydrogel when crosslinked. 16. The composition of claim 15, wherein said hydrogel further comprises a drug or bioactive agent incorporated within its matrix. 17. The composition of claim 16, herein said drug or bio-active agent is selected from the group consisting of thrombo-resistant agents, antibiotic agents, anti-tumor agents, antiviral agents, anti-angiogenic agents, angiogenic agents, anti-inflammatory agents, cell cycle regulating agents, and chemically modified equivalents and combinations thereof. 18. The composition of claim 17, wherein said thrombo-resistant agent is selected from the group consisting of heparin, heparin sulfate, hirudin, hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratan sulfate, lytic agents, urokinase, streptokinase, and chemically modified equivalents and combinations thereof. 19. The composition of claim 17, wherein said antibiotic agent is selected from the group consisting of penicillins, cephalosporins, vancomycins, aminoglycosides, quinolones, polymyxins, erthromycins, tetracyclines, chloramphenicols, clindamycins, lincomycins, sulfonamides, and chemically modified equivalents and combinations thereof. 20. The composition of claim 17, wherein said anti-tumor agent is selected from the group consisting of paclitaxel, mechlorethamine, chlorambucil, cyclophosphamide, melphalan, ifosfamide, methotrexate, 6-mercaptopurine, 5-fluorouracil, cytarabine, vinblastine, vincristine, etoposide, doxorubicin, daunomycin, bleomycin, mitomycin, carmustijne, lomustine, cisplatin, interferon, asparaginase, tamoxifen, flutamide, and chemically modified equivalents and combinations thereof. 21. The compositions of claim 17, wherein said anti-viral agent is selected from the group consisting of amantadines, rimantadines, ribavirins, idoxuridines, vidarabines, trifluridines, acyclovirs, ganciclovirs, zidovudiens, foscarnets, interferons, and chemically modified equivalents and combinations thereof. 22. A covalently crosslinkable composition comprising a water-insoluble copolymer having (i) a bioresorbable region; (ii) a hydrophilic region; and (iii) a plurality of crosslinkable functional groups per polymer chain, wherein the copolymer is selected from the group consisting of di-block copolymers, tri-block copolymers, and star copolymers. 23. The covalently crosslinkable composition of claim 22, wherein said tri-block copolymer has the general formula: wherein A is the bioresorbable region, B is the hydrophilic region, and x is the crosslinkable functional group.

Details for Patent 6,028,164

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2017-08-18
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2017-08-18